Cuvitru drug class?

What class is Cuvitru in?

Cuvitru is an immune globulin therapy, specifically a subcutaneous infusion of human immunoglobulin (IgG). It is used to replace antibodies in people who have antibody deficiencies.

Is Cuvitru an IVIG or SCIG?

Cuvitru falls under subcutaneous immunoglobulin (SCIG) products. Unlike IVIG, which is given intravenously, Cuvitru is administered under the skin.

What conditions is Cuvitru typically used for?

Cuvitru is used for antibody replacement in patients with primary immunodeficiency disorders (and related IgG deficiency states where IgG replacement is indicated).

Is Cuvitru a monoclonal antibody or vaccine?

No. Cuvitru is not a monoclonal antibody and it is not a vaccine. It is a pooled human IgG product for passive immunoglobulin replacement.

Patents and manufacturer context

For up-to-date information on Cuvitru’s product and related patent status, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/